­
­
­
­

Inventi Impact: Endocrinology

Articles

  • Inventi:hec/33043/20
    Combined Therapy of Somatostatin Analogues with Pegvisomant for the Treatment of Acromegaly: A Meta-Analysis of Prospective Studies
    Research 2021 : January - March
    Lingyun Ma, Daohuang Luo, Ting Yang, Songtao Wu, Min Li, Chaoyang Chen, Shuang Zhou, Lingyue Ma, Ye Wu, Ying Zhou, Yimin Cui

    Background: Acromegaly is a rare, chronic and severe disease. Drug therapy including somatostatin analogues\n(SAs), dopamine receptor agonists and growth hormone receptor antagonists (pegvisomant, PEG) are commonly\nused to treat patients who do not respond to surgery. The use of combination therapy with PEG and SAs has\nbecome more common over the last decade. We performed this study to accurately evaluate the effect of\ncombination therapy of SAs with PEG on acromegalic patients.\nMethods: PubMed, EMBASE, The Cochrane Library, ClinicalTrials.gov, Scopus, Web of Science, Chinese Biomedical\nLiterature Database and Trip database were searched for relevant studies. Prospective clinical trials treating\nacromegaly with the co-administration of SAs and PEG were included. We performed a meta-analysis by using\nStata 12.1. Sensitivity analysis was conducted to explore heterogeneity..........................

    How to Cite this Article
    Attribution/ CC Compliant Citation: Ma, Lingyun, et al. \"Combined therapy of somatostatin analogues with pegvisomant for the\ntreatment of acromegaly: a meta-analysis of prospective studies.\" (2020).\nhttps://doi.org/10.1186/s12902-020-0545-2\nhttp://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text